Polynovo Ltd

MFJ

Company Profile

  • Business description

    Polynovo earns majority of its revenue from U.S sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

  • Contact

    320 Lorimer Street
    Unit 2
    Port MelbourneVIC3207
    AUS

    T: +61 386814050

    https://www.polynovo.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    Employees

    301

Stocks News & Analysis

stocks

ASX rare earths play looks to expand production

The largest rare-earth producer outside of China acquires competitor to increase production.
stocks

Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation

Draft IPO filing shows a company growing faster than its annual results can capture.
stocks

The 10 best US companies to invest in now

The stocks of these high-quality companies look cheap today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,903.5044.300.50%
CAC 407,876.8942.790.55%
DAX 4025,408.24154.030.61%
Dow JONES (US)51,267.9090.940.18%
FTSE 10010,540.1042.160.40%
HKSE24,280.56240.221.00%
NASDAQ27,477.31286.451.05%
Nikkei 22570,683.98737.121.05%
NZX 50 Index13,700.121.100.01%
S&P 5007,773.9551.230.66%
S&P/ASX 2008,735.7049.300.57%
SSE Composite Index3,842.1911.740.31%

Market Movers